CN101039925A - 作为选择性雌激素受体调节剂的苯并氧氮杂䓬衍生物 - Google Patents

作为选择性雌激素受体调节剂的苯并氧氮杂䓬衍生物 Download PDF

Info

Publication number
CN101039925A
CN101039925A CNA2005800351717A CN200580035171A CN101039925A CN 101039925 A CN101039925 A CN 101039925A CN A2005800351717 A CNA2005800351717 A CN A2005800351717A CN 200580035171 A CN200580035171 A CN 200580035171A CN 101039925 A CN101039925 A CN 101039925A
Authority
CN
China
Prior art keywords
hydrogen
hydroxyl
compound
acyloxy
siloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800351717A
Other languages
English (en)
Chinese (zh)
Inventor
J·C·兰特
Z·隋
J·J·费奥尔德利索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101039925A publication Critical patent/CN101039925A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA2005800351717A 2004-08-17 2005-07-28 作为选择性雌激素受体调节剂的苯并氧氮杂䓬衍生物 Pending CN101039925A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60205404P 2004-08-17 2004-08-17
US60/602,054 2004-08-17

Publications (1)

Publication Number Publication Date
CN101039925A true CN101039925A (zh) 2007-09-19

Family

ID=35431802

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800351717A Pending CN101039925A (zh) 2004-08-17 2005-07-28 作为选择性雌激素受体调节剂的苯并氧氮杂䓬衍生物

Country Status (6)

Country Link
US (1) US20060040917A1 (https=)
EP (1) EP1778656A1 (https=)
JP (1) JP2008509999A (https=)
CN (1) CN101039925A (https=)
CA (1) CA2576747A1 (https=)
WO (1) WO2006023242A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103080121B (zh) * 2010-09-20 2015-11-25 瑞士诺华动物保健有限公司 用于制备在二脱氧甲基己糖环的C-4”处被环氧基团修饰的9-脱氧-9a-氮杂-9a-高红霉素A的新方法
KR101363472B1 (ko) 2011-03-30 2014-02-17 한국화학연구원 신규한 크로멘 유도체, 이의 약학적으로 허용가능한 염 또는 이의 이성질체, 이의 제조방법 및 이를 포함하는 ｐａｒ-1 관련 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
DE19833786A1 (de) * 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE321754T1 (de) * 2001-05-22 2006-04-15 Lilly Co Eli 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren

Also Published As

Publication number Publication date
US20060040917A1 (en) 2006-02-23
JP2008509999A (ja) 2008-04-03
EP1778656A1 (en) 2007-05-02
CA2576747A1 (en) 2006-03-02
WO2006023242A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
CN1133635C (zh) 用于结合黄体酮受体的氰基吡咯类
CN1187366C (zh) 新型的19－去－孕甾烯衍生物
CN1298409A (zh) 具有激动或拮抗激素性质的20－酮基－11β－芳基甾族化合物及其衍生物
CN1652768A (zh) 用于节育和激素替代疗法的具有孕酮受体调节活性的5－{2－羟基－3－[′1－(3－三氟甲基苯基)－环丙基]－丙酰氨基}－2－苯并[c]呋喃酮及相关化合物
CN1303391A (zh) 具有激素促效剂或拮抗剂性质的17β－氨基与羟基氨基－11β－芳基甾族化合物及其衍生物
CN1745085A (zh) 用作选择性雌激素受体调节剂的新的含杂原子的四环衍生物
CN1802348A (zh) 巯基－苯基－萘基－甲烷衍生物及其制备
CN1208341C (zh) S－取代的11β－苯甲醛肟－雌－4,9－二烯一硫羟酸酯、其制备方法以及包含这些化合物的药物制剂
CN1278809A (zh) 取代的苯并二氢吡喃衍生物
CN1348461A (zh) 具有激动或拮抗激素性质的17β－酰基－17α－丙炔基－11β－芳基甾族化合物及其衍生物
CN1166680C (zh) 新颖的雄激素
CN101039925A (zh) 作为选择性雌激素受体调节剂的苯并氧氮杂䓬衍生物
CN1878786A (zh) 新的I型17β－羟化类固醇脱氢酶抑制剂
CN1620457A (zh) 作为雌激素受体调节剂的四环杂环化合物
CN1751059A (zh) 具有抗肿瘤活性的2－取代的雌－1,3,5(10)－三烯－3－基氨基磺酸酯
CN1288007A (zh) 6－羟基－3－(4－[2－(哌啶－1－基)乙氧基]苯氧基)－2－(4－甲氧基苯基)苯并[b]噻吩盐酸盐的新晶形
CN101060838A (zh) 用作类固醇性激素受体调节剂的新的含杂原子的四环衍生物
CN1659181A (zh) 作为选择性雌激素的9α－取代的雌三烯
CN100345863C (zh) 作为雌激素受体调节剂的雌三烯并[3,2－b]/[3,4－c]吡咯衍生物
CN1089264A (zh) 异苯并呋喃酮衍生物
CN1798721A (zh) 作为选择性的雌激素受体蛋白调节剂的环己基衍生物
CN1305457A (zh) 新型抗雌激素及其制备方法和药物用途
CN1268624C (zh) 6－羟基－3－(4－[2－(哌啶－1－基)乙氧基]苯氧基)－2－(4－甲氧基苯基)苯并[b]噻吩盐酸盐的新晶形
CN1771243A (zh) 用作类固醇硫酸酯酶抑制剂的氨基磺酸苯并噻吩酯衍生物
CN1247541A (zh) 在11位取代的类固醇,它们的制备方法,它们作为药物的应用以及含有它们的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070919